Trial · NCT01465659
Results by group149
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 149
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Determine the Maximum Tolerated Dose (MTD) of Temozolomide in Combination With 400 mg Pazopanib in Patients With Advanced Pancreatic Neuroendocrine Tumor (PNET) in Phase I | Cohort 1/Cohort -1/Cohort -2 - Temozolomide and Pazopanib | 75 | mg/m2 | ||
| Overall Response Rate (ORR) in Patients With Advanced Neuroendocrine Tumors (PNET) Treated With Temozolomide and Pazopanib Combination Treatment at the RP2D in Phase II | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | Participants | ||
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | Any AE | 7 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | Any AE | 5 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | Any AE | 6 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | Any AE | 11 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | AE related to treatment | 7 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | AE related to treatment | 5 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | AE related to treatment | 6 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | AE related to treatment | 11 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | SAE | 3 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | SAE | 3 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | SAE | 1 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | SAE | 1 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | SAE related to treatment | 3 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | SAE related to treatment | 1 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | SAE related to treatment | 1 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | SAE related to treatment | 1 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | Grade 5 SAE | 0 | patients | |
| Number of Patients Who Experience Toxicity Events Undergoing This Treatment. | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | Grade 5 SAE | 1 | patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01465659/results